- Home
- MBC vs IRON Comparison
MBC vs IRON Comparison
Compare MBC & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBC
- IRON
- Stock Information
- Founded
- MBC 1954
- IRON 2017
- Country
- MBC United States
- IRON United States
- Employees
- MBC N/A
- IRON N/A
- Industry
- MBC Agricultural Chemicals
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- MBC Industrials
- IRON Health Care
- Exchange
- MBC Nasdaq
- IRON Nasdaq
- Market Cap
- MBC 1.4B
- IRON 1.4B
- IPO Year
- MBC N/A
- IRON N/A
- Fundamental
- Price
- MBC $10.20
- IRON $51.61
- Analyst Decision
- MBC Strong Buy
- IRON Strong Buy
- Analyst Count
- MBC 1
- IRON 10
- Target Price
- MBC $15.00
- IRON $93.40
- AVG Volume (30 Days)
- MBC 779.8K
- IRON 372.4K
- Earning Date
- MBC 08-05-2025
- IRON 08-07-2025
- Dividend Yield
- MBC N/A
- IRON N/A
- EPS Growth
- MBC N/A
- IRON N/A
- EPS
- MBC 0.77
- IRON N/A
- Revenue
- MBC $2,722,600,000.00
- IRON N/A
- Revenue This Year
- MBC N/A
- IRON N/A
- Revenue Next Year
- MBC $4.37
- IRON N/A
- P/E Ratio
- MBC $13.23
- IRON N/A
- Revenue Growth
- MBC 1.30
- IRON N/A
- 52 Week Low
- MBC $9.63
- IRON $30.82
- 52 Week High
- MBC $20.67
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- MBC 45.26
- IRON 56.99
- Support Level
- MBC $9.86
- IRON $48.87
- Resistance Level
- MBC $10.35
- IRON $54.13
- Average True Range (ATR)
- MBC 0.39
- IRON 2.31
- MACD
- MBC 0.03
- IRON 0.07
- Stochastic Oscillator
- MBC 37.50
- IRON 67.64
About MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.